Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Innovative Clinical Trial Design: Commercial vs Open-Source Software? Why Not Both?

In the ever-changing field of clinical trial design, there is often a need to evaluate design options quickly and efficiently. But when it comes to evaluating options, which is better: commercial or open-source software? And does it need to be a question of either-or?

Read full article

Perspectives on Enquiry and Evidence

May 26, 2022

Method of Estimation with application to the COVID-19 Pandemic

When constructing estimands a key question that arises is how to handle intercurrent events and missing data. In a...

Read article

August 7, 2020

Creating a Synthetic Control from Your Natural History Study

Recently a biotech approached Cytel for support with a Phase 2 Study in oncology. Regulators had requested a natural...

Read article

August 4, 2020

Estimands and their Implications on Clinical Studies

Last year, Paul Terrill, Associate Principal of Strategic Consulting at Cytel, presented an engaging webinar on the...

Read article

July 15, 2020

Three Reasons Why Oncology Trials Need Clear Estimands

Unlike many therapeutic areas, oncology benefits from having standardized endpoints like overall survival and...

Read article

November 5, 2019

Drug Development in Rare Diseases - Innovation in Statistical Thinking

Cytel is delighted to have Kannan Natarajan speaking at the “Complex Innovative Trial Design Symposium and East User...

Read article

July 8, 2019

Estimands are not just a statistical issue- Q&As and webinar replay

Cytel recently hosted a very well-attended and engaging webinar on the topic of “Estimands, not just a statistical...

Read article

July 2, 2018

Highlights from the PSI 2018 Conference

A number of the Cytel team were in Amsterdam, 3rd- 6th June 2018 for the PSI Conference. This year’s conference was...

Read article